Fog/Mist 48°
Tag:

Molnupiravir

News
NJ Company's Experimental COVID Drug Could Be Major Game-Changer NJ Company's Experimental COVID Drug Could Be Major Game-Changer
NJ Company's Experimental COVID Drug Could Be Major Game-Changer New Jersey drug manufacturer Merck & Co. and Ridgeback Biotherapeutics on Friday said the new experimental COVID-19 drug significantly reduces hospitalization time and chance of death for 50 percent of patients with mild to moderate cases. In light of the new findings, the Kenilworth-based company has stopped the drug's trial to apply for emergency use authorization. Molnupiravir is an oral pill and inhibits the replication of the virus inside of the body. “The news of the efficacy of this particular antiviral is obviously very good news,” White House chief medical advisor Dr. Ant…

SHARE

by Cecilia Levine
News
COVID-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus COVID-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus
Covid-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19. Molnupiravir is being tested in a Phase 2/3 trial set to be completed in May. Merck will be provided with up to  $268.8 million in funding from the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services. Associate Professor of Medicine at the University of North Carolina School of Medicine William Fis…

SHARE

by Cecilia Levine